Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies

Documenti analoghi

• Effectiveness and tolerability of dolutegravir/lamivudine in virologically suppressed people with HIV at 96 weeks in a multicentre cohort
  di: Inés Suárez‐García, et al.
  Pubblicazione: (2025)
• Impact of HBV serological status on HIV virological efficacy of two‐drug antiretroviral regimens: A retrospective observational study on virologically suppressed people with HIV switching to lamivudine/dolutegravir
  di: Pierluigi Francesco Salvo, et al.
  Pubblicazione: (2025)
• Real‐world effectiveness and safety of switching to dolutegravir/lamivudine among people living with HIV‐1 aged over 50 years who are virologically suppressed
  di: C. Piñeiro, et al.
  Pubblicazione: (2024)
• High rates of viral suppression in pregnancy drop postpartum in South African women on tenofovir‐lamivudine‐dolutegravir: a prospective cohort study
  di: Elaine J. Abrams, et al.
  Pubblicazione: (2025)
• Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain
  di: Santiago Moreno Guillén
  Pubblicazione: (2017)